Antibiotic prescriptions and cycles of Mycoplasma pneumoniae infections in Norway: can a nationwide prescription register be used for surveillance?
Mycoplasma pneumoniae outbreaks cause increased use of macrolides and tetracyclines. We aimed to investigate whether drug use data, in addition to laboratory data, could improve understanding of the spread of M. pneumoniae epidemics. Number of users of Mycoplasma antibiotics (erythromycin, doxycycline, clarithromycin) per week and county of residence in an indicator age group (6-12 years) was retrieved from the Norwegian prescription database for the epidemic season 2011-2012 and compared to non-epidemic seasons. In 2011, increased use of Mycoplasma antibiotics was first observed in September on the west coast of Norway. The Norwegian laboratory-based surveillance system showed the first increase in positive tests in August 2011 and an epidemic was announced on 25 October 2011. At that time the use of Mycoplasma antibiotics had already exceeded three times the use in non-epidemic periods. Data for three counties from the regional microbiological laboratories showed that the increase in number of positive samples coincided in time with the increase in prescription data. Laboratory data cannot accurately determine the extent of an epidemic, and drug use data cannot identify the cause. Establishing a systematic interaction between the two monitoring systems will enhance surveillance and probably contribute to improved infection control and prudent antibiotic prescribing.
Department of Pharmacoepidemiology,Norwegian Institute of Public Health,Oslo,Norway.
H S
HS
Blix
Department of Bacteriology and Immunology,Norwegian Institute of Public Health,Oslo,Norway.
D F
DF
Vestrheim
Department of Pharmacoepidemiology,Norwegian Institute of Public Health,Oslo,Norway.
V
V
Hjellvik
Department of Microbiology,Vestfold Hospital Trust,Tønsberg,Norway.
D
D
Skaare
Department of Medical Microbiology,St. Olavs Hospital, Trondheim University Hospital,Trondheim,Norway.
A
A
Christensen
Department of Bacteriology and Immunology,Norwegian Institute of Public Health,Oslo,Norway.
M
M
Steinbakk
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002648:Child; D017291:Clarithromycin / Q000627:therapeutic use*; D004318:Doxycycline / Q000627:therapeutic use*; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D058872:Epidemics; D004917:Erythromycin / Q000627:therapeutic use*; D006801:Humans; D009177:Mycoplasma pneumoniae / Q000502:physiology; D009664:Norway / Q000453:epidemiology; D011019:Pneumonia, Mycoplasma / Q000188:drug therapy* / Q000453:epidemiology* / Q000382:microbiology; D062486:Public Health Surveillance
D000900:Anti-Bacterial Agents; D004917:Erythromycin; D017291:Clarithromycin; D004318:Doxycycline
Antibiotics; community epidemics; epidemiology; public health; surveillance system